Rallybio Corporation
Rallybio Corporation, based in New Haven, CT, is dedicated to transforming the treatment landscape for patients with rare diseases by developing innovative therapies that address unmet medical needs. The company focuses on creating profound changes in patient outcomes through its portfolio of assets targeting complement dysregulation, hematology, and metabolic diseases.
With a team of experienced innovators, Rallybio aims to challenge the status quo and deliver best-in-class treatments that have the potential to significantly improve the lives of those affected by rare conditions. Their commitment to advancing science and patient care is reflected in their ongoing research and development efforts, including promising studies on their C5 inhibitor, RLYB116.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.